Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

Immunoglobulin (Ig) G1 antibodies stimulate antibody-dependent cell-mediated cytotoxicity (ADCC). Cetuximab, an IgG1 isotype monoclonal antibody, is a standard-of-care treatment for locally advanced and recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and metastatic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferris, Robert L., Lenz, Heinz-Josef, Trotta, Anna Maria, García-Foncillas, Jesús, Schulten, Jeltje, Audhuy, François, Merlano, Marco, Milano, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505164/
https://www.ncbi.nlm.nih.gov/pubmed/29223828
http://dx.doi.org/10.1016/j.ctrv.2017.11.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505164/
https://www.ncbi.nlm.nih.gov/pubmed/29223828
http://dx.doi.org/10.1016/j.ctrv.2017.11.008

Ejemplares similares